Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$134.50
-$1.43(-1.02%)
At close: 4:00 PM EST
$134.50
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$88.00 - $196.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.05M
Market Cap
$28.78B
Enterprise Value$25.53B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)34.5
Beta1.23
Next Earnings
Jul 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.54
Shares Outstanding151,300,000
10 Day Avg. Volume1,848,323
30 Day Avg. Volume2,045,837
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue5.81
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda18.13
Forecast
1Y Price Target
$158.57Price Target Upside17.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)5.23
Revenue Forecast (FY)$4.57B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained high operating and free cash flow provides durable financial flexibility to fund R&D, scale manufacturing for NovaSeq X, support share buybacks, and absorb cyclic downturns. High cash conversion underpins capital allocation and reduces reliance on external financing over the medium term.
Margin Recovery And ProfitabilityA material rebound in gross and operating margins reflects improved product mix, higher throughput and cost discipline. Durable margin gains imply stronger unit economics for consumables, making earnings and cash flows more resilient and supporting long‑term reinvestment and shareholder returns.
NovaSeq X Installed‑base ScaleRapid NovaSeq X adoption expands a high‑throughput installed base that drives recurring consumables demand and creates scale advantages. Higher throughput per instrument increases consumables pull‑through and strengthens competitive differentiation in sequencing economics over the coming years.
Bears Say
Research & Applied Consumables WeaknessSustained weakness in research sequencing demand reflects funding and spending dynamics in academia and some commercial labs. A prolonged pullback in this segment reduces the core recurring consumables base and constrains top‑line growth potential absent offsetting clinical expansion.
Microarrays DeclineA pronounced microarrays contraction removes a non‑sequencing revenue stream and increases reliance on sequencing consumables. Loss of diversification raises exposure to sequencing market cycles and specific customer segment shifts, potentially amplifying top‑line volatility over multiple quarters.
Mixed Balance Sheet / Leverage ProfileAlthough leverage has improved, materially lower equity after prior loss years leaves less capital cushion and reduces financial flexibility. Moderate leverage limits headroom for large inorganic investments or aggressive capex without altering capital structure, elevating risk in adverse scenarios.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $88.00 and its highest was $196.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $28.78B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Apr 30, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.055 by $0.095.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.23.
How many shares outstanding does Illumina have?
Illumina has 151,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.15 in its last earnings report, beating expectations of $1.055. Following the earnings report the stock price went up 7.133%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$158.57 (17.90% Upside)
$158.57 (17.90% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 789.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.10%
12-Months-Change
Fundamentals
Return on Equity
33.99%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear beat in Q1 with multiple key operational and financial positives: revenue and EPS outperformance, strong clinical consumables growth (~20% ex-China), robust NovaSeq X placements (80+ in the quarter), margin expansion, and an upwardly revised full-year guide. Offsetting items include continued weakness in research & applied consumables (down ~12% ex-China), a 20% decline in microarrays RoW organic, supply constraints on NovaSeq X that require scaling investments, and near-term inflationary pressures impacting Q2 margins. Management framed the negatives as transitory or manageable and emphasized product innovation, strong cash flow, and progress toward 2027 targets.View all ILMN earnings summariesILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$158.57
▲(17.90% Upside)
Technical Analysis
Ownership Overview
2.13% Insiders
28.21% Mutual Funds
0.25% Other Institutional Investors
45.91% Public Companies and Individual Investors